

## Index

- AAIDD. *See* American Association of Intellectual and Developmental Disabilities
- ABA. *See* applied behavioral analysis
- ACA. *See* anterior cerebral arteries
- academic outcomes  
 with epilepsy, 193  
 with FASD, 86  
 with LBW/preterm birth, 7–10  
 prevention strategies for, 8–9  
 special education services, 8  
 with LD  
 for basic academic skills, 118  
 for complex academic skills, 118  
 with pediatric cancer, 171  
 with PHIV, 214–215  
 with SBM, 28  
 clinical treatment practices for, 37  
 IEPs and, 33–34, 35  
 intervention strategies for, 35  
 neuropsychological evaluations of, 32–33
- acquired immune deficiency syndrome (AIDS), 210
- activities of daily living (ADL), with HIV, 213
- acute lymphocytic leukemia (ALL), 162  
 intellectual functioning with, 170
- acute myeloid leukemia (AML), 162
- AD. *See* Alzheimer's disease
- ADA. *See* Americans with Disabilities Act
- ADA Amendments Act (ADAAA) (2008), 54, 117
- adaptive functioning  
 with FASD, 86–87  
 with PHIV, 215
- ADDM Network. *See* Autism and Developmental Disabilities Monitoring Network
- ADHD. *See* attention deficit hyperactivity disorder
- ADL. *See* activities of daily living
- adolescence. *See also* pediatric cancer; pediatric HIV; pediatric ischemic stroke  
 ADHD during, 94  
 HIV and, 215–216
- behavioral and emotional functioning, 216
- cognitive functioning, 215–216
- HAND, 217–219
- intellectual disability syndromes  
 during, 73  
 MS in, 234–235  
 SBM during, 30  
 TBI and, behavioral and emotional outcomes with, 145
- ADT. *See* androgen deprivation therapy
- adult care, transition to  
 with ASD, 54–55  
 for college and university attendance, 54  
 for employment, 54–55  
 for independent living skills, 55  
 in epilepsy treatment, 203  
 with intellectual disability syndromes, 73–74  
 with LD, 130  
 RD, 123  
 after pediatric TBI, 145–146  
 with SBM, 38
- adult patients with cancer. *See* cancers
- AEDs. *See* antiepileptic drugs
- African Americans, SBM among, 24
- age  
 intellectual disability syndromes by, 73–74  
 maternal, DS and, 65  
 MS and, age of onset for, 228
- aging. *See also* adult care  
 HIV and, 212, 217
- AIDS. *See* acquired immune deficiency syndrome
- AIM program. *See* Attention Intervention and Management program
- alcohol-related birth defects (ARBD), 79
- alcohol-related neurodevelopmental disorder (ARND), 79
- alemtuzumab, 237
- ALL. *See* acute lymphocytic leukemia
- all-cause dementia, 269
- Alzheimer's disease (AD), 268, 269–271
- behavioral features, 272
- clinical features, 273
- neuropsychological features, 272
- American Association of Intellectual and Developmental Disabilities (AAIDD), 61
- Americans with Disabilities Act (ADA) (1990), 54, 117
- AML. *See* acute myeloid leukemia
- androgen deprivation therapy (ADT), 165–167
- anticipatory guidance, 37
- antiepileptic drugs (AEDs), 186, 201–202, 204
- antiretroviral (ARV) treatments, 210, 220. *See also* combination antiretroviral therapy
- anxiety, cancer and, 175
- anxiety disorder, 45, 235
- aphasia, 256
- applied behavioral analysis (ABA), 51–52
- aptitude-achievement discrepancy model, 127
- ARBD. *See* alcohol-related birth defects
- ARND. *See* alcohol-related neurodevelopmental disorder
- arteriovenous malformation (AVM), 247
- ARV treatments. *See* antiretroviral treatments
- ASD. *See* autism spectrum disorders
- Asian populations, SBM among, 24
- ATN. *See* Autism Treatment Network
- atomoxetine, 101
- atrial fibrillation, 249
- attention deficit hyperactivity disorder (ADHD)  
 assessment of  
 CPTs, 99–100  
 EF, 100  
 multi-informant, 99–100  
 through rating scales, 99–100
- CBT for, 105–106
- group metacognitive therapy, 105–106
- individual, 105

- comorbid psychiatric disorders, 95  
 CD, 9, 95  
 MDD, 95  
 ODD, 9, 95  
 DSM-5 diagnostic criteria, 93  
 employment outcomes with, 94  
 epidemiology, 93–94  
 gender distribution, 94  
 by race, 94  
 epilepsy and, 192–193, 195  
 etiology, 107  
 functioning domains with, 94–95  
 during adolescence, 94  
 during childhood, 94  
 intervention strategies, 101–107  
 academic, 103  
 BPT, 103–104  
 classroom-based, 102–103  
 cognitive training, 106–107  
 organizational skills, 104–105  
 pharmacological, 101–102  
 physical activity, 107  
 school-based, 102–103  
 self-regulatory, 103  
 skill-based, 104  
 LBW/preterm birth and, 9  
 PAE and, 86–87  
 pathophysiology, 95–97  
 brain development, 96–97  
 through fMRI imaging, 96–97  
 heritability factors, 95–96  
 phenotype, 97  
 pediatric ischemic stroke and, 253  
 SBM and, 26  
 subtypes, 93  
 attention deficits  
 with ASD, 50  
 with DS, 65–66  
 with epilepsy, 192–193  
 with FASD, 84–85  
 iFC and, 5  
 LBW/preterm birth and, 5–7  
 with MS, 234  
 with pediatric, 170  
 with SBM, 25–26  
 intervention strategies,  
 33–34  
 neuropsychological evaluations  
 of, 31  
 with stroke, pediatric ischemic  
 stroke, 253  
 top-down abilities, 26  
 Attention Intervention and  
 Management (AIM) program,  
 152–153  
 Autism and Developmental  
 Disabilities Monitoring  
 (ADDM) Network, 46  
 autism spectrum disorders (ASD)  
 ADHD and, 45  
 adult care practices, transition to,  
 54–55  
 for college and university  
 attendance, 54  
 for employment, 54–55  
 for independent living skills, 55  
 under Americans with Disabilities  
 Act, 54  
 anxiety disorder and, 45  
 clinical features, 45–46  
 clinical practices, 56  
 future research on, 57  
 pharmacological interventions,  
 55–57  
 clinical presentation, 47–51  
 attentional deficits, 50  
 brain development, 48  
 cognitive function, 49  
 EF deficits, 50  
 language skills development,  
 49–50  
 megencephaly, 48  
 memory impairment, 50–51  
 motor function impairments, 51  
 social interaction issues, 9–10, 47  
 diagnostic criteria, 45, 48–49  
 by CDC, 47  
 in DSM-5, 45, 46  
 with fMRI, 48  
 testing instruments in, 48–49  
 epidemiology, 46–47  
 ADDM Network, 46  
 prevalence rates, 46  
 intervention approaches, for  
 children, 51–54  
 ABA, 51–52  
 Early Social Interaction Project,  
 53  
 ESDM, 52–53  
 NDBI, 52  
 PRT, 52  
 LBW/preterm birth and, 9–10  
 mood disorder and, 45  
 pathophysiology, 46–47  
 genetic factors, 46  
 pharmacological interventions,  
 55–57  
 Autism Treatment Network (ATN), 56  
 AVM. *See* arteriovenous malformation  
 Bayley Scales of Infant Development,  
 219–220  
 Behavior Rating Inventory of  
 Executive Function (BRIEF)  
 scores, 7  
 behavioral parent training (BPT),  
 103–104  
 behavioral variant Frontotemporal  
 Dementia (bvFTD), 268, 273  
 behavioral features, 272  
 clinical features, 273  
 neuropsychological features,  
 272  
 specific assessment considerations,  
 279  
 biomarkers, in dementia, 269, 282  
 birth defects. *See also* spina bifida  
 myelomeningocele  
 prevalence rates for, 24  
 by race, 24  
 BPT. *See* behavioral parent training  
 brain attack, 259. *See also* stroke  
 brain development  
 with ADHD, 96–97  
 with ASD, 48  
 with HIV, 212  
 LBW/preterm birth and, 4  
 LD and, 120  
 with SBM, 31  
 white matter development, with  
 megencephaly, 48  
 Brief Repeatable Battery of  
 Neuropsychological Tests  
 (BRB), 236  
 BRIEF scores. *See* Behavior Rating  
 Inventory of Executive  
 Function scores  
 bvFTD. *See* behavioral variant  
 Frontotemporal Dementia  
 cancer-related cognitive impairment  
 (CRCI), 163–164  
 cancers. *See also* pediatric cancer  
 ALL, 162  
 intellectual functioning with, 170  
 AML, 162  
 anxiety and, 175  
 assessment recommendations, 177  
 clinical manifestations, 166–167  
 clinical practice implications, 168  
 CLL, 162  
 CML, 162  
 CNS tumors, 162  
 surgical interventions for,  
 163–164  
 depression and, 175  
 diagnosis rates, 162  
 interventions for, 175–177  
 CBT, 175  
 future research on, 177–179  
 neuropsychological, 176–177  
 pharmacological, 175–176  
 liquid tumors, 162  
 neuroanatomical correlates,  
 166–167  
 neuropsychological functioning,  
 172–173  
 assessment tests, 172  
 genotype associations, 173  
 prevalence rates, 162

## Index

- cancer (cont.)  
 prevention strategies, 170  
 solid tumors, 162  
 treatment factors, functioning  
 influenced by, 163–170  
 chemotherapy, 164  
 CRCI, 163–164  
 CRT, 163–164  
 endocrine therapy, 165–168  
 hormonal therapy, 165–168  
 HSCT, 164–165  
 radiation therapy, 165  
 SES as factor in, 169
- cART therapy. *See* combination  
 antiretroviral therapy
- CAS. *See* Cognitive Assessment System
- CBT. *See* cognitive behavioral therapy
- CD. *See* conduct disorder
- Centers for Disease Control (CDC)  
 ASD diagnostic criteria, 47  
 FASD estimates, 80  
 intellectual disability rates, 61–62
- central nervous system (CNS) tumors,  
 162  
 surgical interventions, 163
- cerebral atrophy, 254
- cerebral palsy (CP), 3
- cerebral sinovenous thrombosis  
 (CSVT), 244  
 ischemic stroke, 244
- cerebral small vessel disease (CSVD),  
 247, 248, 254
- cerebral vascular accident, epilepsy  
 and, 188
- chemoprotectants, 169
- chemotherapy, 164
- Chiari-II malformation, 25
- Chicago Multiscale Depression  
 Inventory, 262
- children. *See* infants and children
- cholesterol level management, 249
- chronic lymphocytic leukemia (CLL),  
 162
- chronic myeloid leukemia (CML), 162
- chronic traumatic encephalopathy  
 (CTE), 146–147
- CIFASD. *See* Collaborative Initiative  
 on Fetal Alcohol Spectrum  
 Disorders
- CIS. *See* clinically isolated syndrome
- clinically isolated syndrome (CIS), 233
- CLL. *See* chronic lymphocytic  
 leukemia
- CML. *See* chronic myeloid leukemia
- CNS tumors, 162  
 “cocktail party syndrome,” 32
- Cognitive Assessment System (CAS),  
 31
- cognitive behavioral therapy (CBT)  
 for ADHD, 105–106  
 group metacognitive therapy,  
 105–106  
 individual, 105  
 in cancer interventions, 175  
 for epilepsy, 202–203
- cognitive function  
 with ASD, 49  
 with FASD, 81–87  
 academic outcomes, 86  
 EF, 84–85  
 language skills development,  
 85  
 learning impairments, 85–86  
 memory impairments, 85–86  
 with HIV, 212–213  
 in adolescence, 215–216
- LBW/preterm birth, 5
- metacognition, 26  
 with MS, 234–235  
 in adults, 234  
 attention deficits, 234  
 in children and adolescents,  
 234–235  
 EF, 235  
 language skills development,  
 234–235  
 memory deficits, 234  
 with PHIV, 213–215  
 with stroke, 263–263  
 pediatric ischemic, 257–258  
 with TBI, 141, 142–144
- cognitive rehabilitation  
 for HAND, 221  
 for MS, 238–239
- cognitive reserve, 212
- Cogstate program, for pediatric cancer  
 assessment, 178–179
- Collaborative Initiative on Fetal  
 Alcohol Spectrum Disorders  
 (CIFASD), 84
- combination antiretroviral (cART)  
 therapy, 212, 217, 220  
 for HAND, 220–221
- Comprehensive Assessment of Spoken  
 Language, 32
- conduct disorder (CD), 9, 95
- continuous performance tests (CPTs),  
 99–100
- corticosteroids, 237
- CP. *See* cerebral palsy
- CPTs. *See* continuous performance  
 tests
- cranial radiation therapy (CRT),  
 163–164  
 for pediatric cancer, use limitations  
 in, 169
- CRCI. *See* cancer-related cognitive  
 impairment
- CRT. *See* cranial radiation therapy
- CSVD. *See* cerebral small vessel disease
- CSVT. *See* cerebral sinovenous  
 thrombosis
- CTE. *See* chronic traumatic  
 encephalopathy
- culture, epilepsy considerations  
 influenced by, 197  
 neuropsychological assessment of,  
 200
- daclizumab, 237
- DAI. *See* diffuse axonal injury
- DART. *See* Dual Attention to Response  
 Task
- delayed onset dementia, 275
- dementia  
 AD, 268, 269–271  
 behavioral features, 272  
 clinical features, 273  
 neuropsychological features, 272  
 all-cause, 269  
 assessment strategies  
 comprehensive, 278–279  
 neuropsychological, 276–277  
 normative considerations in, 279  
 screening tests, 277–278  
 serial, 279  
 specific considerations in,  
 279–280  
 test design for, 282  
 utility of, 282
- bvFTD, 268, 273  
 behavioral features, 272  
 clinical features, 273  
 neuropsychological features, 272  
 specific assessment  
 considerations, 279  
 causes of, 270  
 common causes of, 268  
 comprehensive assessment of,  
 278–279  
 definitions, 268  
 diagnostic criteria, 268–269  
 biomarkers in, 269, 282  
 clinical overview, 281  
 NCDs, 268–269  
 epidemiology of, 271  
 with epilepsy, 194–195  
 frontotemporal, 270  
 interventions for, 280–282  
 clinical overview, 281  
 non-pharmacological, 280–281  
 pharmacological, 280
- LBD, 268, 270, 271–273  
 behavioral features, 272  
 clinical features, 273  
 neuropsychological features, 272  
 specific assessment  
 considerations, 279–280  
 neuroimaging in, 277  
 prevention strategies, 275

- risk factors, 273–274  
 support factors for, 275–276  
   for delayed onset, 275  
   limited, 276  
 from TBI, 146–147  
   CTE, 146–147  
 unsupported factors for, 276
- Dementia with Lewy Bodies. *See* Lewy Body Disease
- depression  
 cancer and, 175  
 Chicago Multiscale Depression Inventory, 262  
 with MS, 235  
 stroke and, 262
- developmental MD, 121
- diabetes, management of, 249
- Diagnostic and Statistical Manual of Mental Disorders, 5th Edition* (DSM-5)  
 ADHD diagnostic criteria, 93  
 ASD, 45, 46  
 intellectual disability, 61, 63  
 LD diagnostic criteria, 117–119  
   for basic academic skills, 118  
   for complex academic skills, 118  
   IQ levels in, 118–119, 127
- diet and nutrition  
 ketogenic, 202  
 stroke prevention and, 249
- diffuse axonal injury (DAI), 140
- diffuse TBI, 140
- dimethyl fumarate, 237
- Donepezil, 173–174
- Down syndrome (DS), 64–66  
 attention deficits with, 65–66  
 epidemiology, 64–65  
 etiology, 64–65  
   chromosome 21 overexpression, 64–65  
   maternal age, 65  
   race and ethnicity factors, 65  
 language development and, 65–66  
 medical comorbidities, 65  
 motor function and, 65–66  
 neurobehavioral profile, 65–66  
 neurological basis, 66  
 phenotype, 65  
 prevalence rates, 64–65  
 survival prognosis, 66
- DS. *See* Down syndrome
- DSM-5. *See* *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition*
- Dual Attention to Response Task (DART), 31
- dyslexia. *See also* reading disorder  
 heritability of, 120
- Early Social Interaction Project, 53
- Early Start Denver Model (ESDM), 52–53
- Education for All Handicapped Children Act (1975), 116
- education services. *See* special education services
- EF. *See* executive functioning
- ELBW. *See* extremely low birth weight
- employment outcomes  
 with ADHD, 94  
 with ASD, 54–55
- endocrine therapy, 165–168
- endoscopic third ventriculostomy with choroid plexus cauterization (ETV/CPC), 38–39
- EP birth. *See* extremely preterm birth
- epilepsy  
 ADHD and, 192–193, 195  
 in adults  
   cognitive manifestations, 193–195  
   psychoclinical features, 193–195  
 assessment techniques, 188  
 behavioral manifestations of, 192  
 cerebral vascular accident and, 188  
 in children  
   cognitive manifestations, 188–193  
   psychosocial features, 195  
 clinical practice implications, 205–206  
 cognitive manifestations of, 188–195  
   academic outcomes, 193  
   attention deficits, 192–193  
   EF deficits, 193  
   memory deficits, 193  
 cultural considerations across lifespan, 197  
 neuropsychological assessment of, 200  
 defined, 186  
 dementia with, 194–195  
 EF and, 193  
   neuropsychological assessment of, 201  
 ischemic stroke and, 188  
 longer-term outcomes with, 197  
 longitudinal development studies, 197  
 medically refractory, 192  
 memory functions and, 193  
   neuropsychological assessment of, 200–201  
 mental health disorders with, 202–203  
 neuropsychological aspects of, 189–191  
 neuropsychological assessment of, 199–201  
   cultural considerations, 200  
   for EF, 201
- ILAE Neuropsychology Task Force, 199–200, 204, 205–206  
 for intellectual functioning, 200  
 language skills, 200  
 for memory, 200–201  
 new-onset, 194  
 prevalence rates, 186–187  
 prevention strategies, 187  
   early, 187  
   against infection, 187  
 PTE, 187–188  
 seizures, 186  
 PNES, 197–199  
 after TBI, 187–188  
 treatment strategies, 201–202  
   with AEDs, 186, 201–202, 204  
   with CBT, 202–203  
   through ketogenic diet, 202  
   transition to adult care, 203  
   VNS, 202
- ESDM. *See* Early Start Denver Model
- ETV/CPC. *See* endoscopic third ventriculostomy with choroid plexus cauterization
- executive functioning (EF)  
 with ADHD, 100  
 with ASD, 50  
 BRIEF scores, 7  
 epilepsy and, 193  
   neuropsychological assessment of, 201  
 with FASD, 84–85  
 with HIV, 212–213  
 LBW/preterm birth and, 5–7  
 with MS, 235  
 neuroanatomical correlates of, 7  
 with pediatric cancer, 170  
 with SBM, 26–27  
   clinical treatment practices for, 37  
   intervention strategies for, 34  
   neuropsychological evaluations of, 31  
 with stroke, 257–257  
 pediatric ischemic stroke, 253
- Expanded Disability Status Scale, 233–234
- extremely low birth weight (ELBW), 2
- extremely preterm (EP) birth, 2
- facilitative intervention training (FIT), 106–107
- families, functioning skills for, with SBM, 29–30  
 clinical manifestations, 29–30  
 interprofessional team partnering with, 36–37  
 intervention strategies for, 35–36  
 neuropsychological evaluations of, 33  
 SES factors, 29–30

## Index

- families, TBI and, psychosocial outcomes for, 145  
 FAS. *See* fetal alcohol syndrome  
 FASD. *See* fetal alcohol spectrum disorders  
 fatigue, with MS, 235  
 females. *See* women  
 fertility treatments, preterm birth rates and, 2  
 fetal alcohol spectrum disorders (FASD)  
   ARBD, 79  
   ARND, 79  
   behavioral functioning, 87  
     neuroanatomical correlates, 82–83  
   CDC estimates, 80  
   during childhood, 82–83  
   clinical care practices, 89–90  
   cognitive impairments, 81–87  
     academic outcomes, 86  
     EF, 84–85  
     language skills development, 85  
     learning impairments, 85–86  
     memory impairments, 85–86  
   defined, 79  
   diagnostic criteria, 79  
   epidemiology, 80  
   FAS, 79  
     pFAS, 79  
   interventions, 88–89  
     future directions for, 90  
     non-pharmacological, 88–89  
     pharmacological, 88  
   neuropsychological impairments, 81–87  
     adaptive functioning, 86–87  
     assessments of, 87  
     attentional difficulties, 84–85  
     CIFASD program, 84  
     intellectual disability, 82–84  
     motor function, 86  
     visual-spatial processing, 85  
   NIAAA guidelines, 79  
   PAE, 79, 81  
     ADHD and, 86–87  
     ND-PAE, 79–80  
   pathophysiology, 80  
   prevention strategies, 80–81  
     UPPSs, 81  
   psychopathology with, 87  
   psychosocial functioning, 87  
 fetal alcohol syndrome (FAS), 79  
   pFAS, 79  
 fingolimod, 237  
 FIT. *See* facilitative intervention training  
 Flair MRI, 247–248  
 fMRI. *See* functional magnetic resonance imaging  
 focal TBI, 140  
 Fragile X syndrome (FXS), 66–67  
   ADHD and, 66  
   ASD and, 66  
   comorbidities, 66  
   epidemiology, 66  
   etiology, 66  
   gender factors, 67  
   long-term prognosis, 67  
   neurobehavioral profile, 67  
   neurological basis, 67  
   phenotype, 66  
   prevalence, 66  
 frontotemporal dementia, 270  
 Full Scale IQ (FSIQ), 68  
 functional adaptation, with SBM, 30  
   intervention strategies for, 36  
   neuropsychological evaluations of, 33  
 functional magnetic resonance imaging (fMRI)  
   for ADHD, 96–97  
   for ASD diagnosis, 48  
 FXS. *See* Fragile X syndrome  
 gender. *See also* males; women  
   ADHD and, 94  
   FXS and, 67  
   long-term prognosis by, 67  
   MS and, 228  
 glatiramer acetate, 237  
 glucocorticoids, 168–169  
 goal-setting. *See* metacognition  
 Gordon Diagnostic System, 31  
 group metacognitive therapy, 105–106  
 HAND. *See* HIV-associated neurocognitive disorders  
 health-related quality of life (HRQoL)  
   with HIV, 213, 217  
   with SBM, 29  
 hematopoietic stem cell transplant (HSCT), 164–165  
 hemispatial neglect, 256  
 hemorrhagic stroke, 244, 247  
 Hispanic populations, SBM among, 24  
 HIV. *See* human immunodeficiency virus  
 HIV-associated neurocognitive disorders (HAND), 211, 212  
   in adolescents, 217–219  
   in adults, 217  
   cART and, 220–221  
   in children, 217–219  
   cognitive rehabilitation, 221  
   development of, 216–217  
   hormonal therapy, 165–168  
 HRQoL. *See* health-related quality of life  
 HSCT. *See* hematopoietic stem cell transplant  
 human immunodeficiency virus (HIV). *See also* HIV-associated neurocognitive disorders;  
   pediatric HIV  
   in adolescence, 215–216  
     behavioral and emotional functioning, 216  
     cognitive functioning, 215–216  
   HAND, 217–219  
   adults with  
     evidence-based guidelines, 221  
     HAND, 217  
   aging and, 212, 217  
   AIDS and, 210  
   clinical manifestation, 212–216, 222  
   ADLs, 213  
   behavioral function, 213  
   cognitive function, 212–213  
   EF, 212–213  
   emotional functioning, 213  
   motor function, 213  
   cognitive functioning with, 212–213  
     in adolescence, 215–216  
     in infants and children, 213–215  
   cognitive reserve, 212  
   development history for, 210  
   epidemiology, 211–212  
     UNAIDS projections, 211  
   HRQoL with, 213, 217  
   interventions for, 210–211  
   longitudinal development, 216–223  
   mood disorders with, 213  
   neuropsychological development, 216–223. *See also* HIV-associated neurocognitive disorders  
   assessment methods, 219–220  
   pathophysiology, 211–212  
   brain development, 212  
   CNS damage, 211. *See also* HIV-associated neurocognitive disorders  
   in perinatal acquisition, 211–212  
   prevalence rates, 211  
   prevention, 212  
   research on, 210–211  
   treatment strategies  
     ARV, 210, 220  
     cART, 212, 217, 220–221  
     evidence-based guidelines, 223  
 hybrid models, for LD testing, 128  
 hydrocephalus, 25  
 hypercholesterolemia, 249  
 hyperfractionation, 169  
 ICD-10. *See* International Classification of Diseases

- IEP. *See* individualized education program
- iFC. *See* intrinsic functional connectivity
- ILAE Neuropsychology Task Force, 199–200, 204, 205–206
- individualized education program (IEP), 33–34, 35  
 development strategies for, 116
- Individuals with Disabilities Education Act (1990), 116
- infants and children. *See also* pediatric cancer; pediatric HIV; pediatric ischemic stroke
- ADHD in, 94
- ASD and, intervention approaches for, 51–54
- ABA, 51–52
- Early Social Interaction Project, 53
- ESDM, 52–53
- NDBI, 52
- PRT, 52
- epilepsy in
- cognitive manifestations, 188–193
- psychosocial features, 195
- FASD during, 82–83
- intellectual disability syndromes
- from environmental exposure, 63–64
- from infants to preschool age, 73
- during school age, 73
- MS in, 230
- WISC-V, 31
- intellectual disability syndromes. *See also* Down syndrome; Fragile X syndrome; Williams Syndrome
- during adolescence, 73
- adult care with, transition to, 73–74
- assessment considerations, 73
- by age, 73–74
- behavior observation, 73
- sensory and motor conditions, 73
- in childhood
- from environmental exposure, 63–64
- from infants to preschool age, 73
- school age, 73
- clinical manifestations, 69
- defined, 61
- diagnostic criteria
- AAIDD, 61
- classification systems, 62–63
- DSM-5, 61, 63
- dual, 73
- ICD-10, 61, 63
- epidemiology, 61–62
- etiology, 62–64
- environmental exposure, during
- childhood, 63–64
- genetic disorders, 63
- LBW/preterm birth, 63
- prenatal risk factors, 63
- from TBI, 63, 64
- with FASD, 82–84
- interventions for, 71–73
- resources for, 74
- neuropsychological assessment, 68–71
- PKU, 64
- prevalence for, 61–62
- CDC estimates, 61–62
- prevention strategies, 64
- treatment strategies, 71–72
- intellectual functioning
- with ALL, 170
- with epilepsy, 200
- with pediatric cancer, 170
- with pediatric ischemic stroke, 250–252
- intelligence quotient (IQ)
- FSIQ, 68
- LBW/preterm birth and, 5
- with LD, 118–119, 127
- International Classification of Diseases, 10th Edition (ICD-10), intellectual disability diagnosis, 61, 63
- intra-individual differences model, 126–127
- intrauterine growth restriction (IUGR), LBW/preterm birth and, 2
- intrinsic functional connectivity (iFC), 5
- IQ. *See* intelligence quotient
- ischemic stroke, 188
- CSVT, 244
- IUGR. *See* intrauterine growth restriction
- Joint United Nations Programme on HIV/AIDS (UNAIDS), 211
- Kanner, Leo, 48
- Kaufman Test of Educational Achievement-Third Edition, 32
- ketogenic diet, 202
- language skills
- with ASD, 49–50
- “cocktail party syndrome,” 32
- Comprehensive Assessment of Spoken Language, 32
- with DS, 65–66
- with epilepsy, 200
- with FASD, 85
- with MS, 234–235
- with pediatric ischemic stroke, 252
- with PHIV, 214–215
- with SBM, 27
- intervention strategies for, 34
- neuropsychological evaluations of, 31–32
- late preterm (LP) birth, 2
- LBD. *See* Lewy Body Disease
- LBW. *See* low birth weight
- learning disabilities (LD). *See also* academic outcomes
- definitions, 116–117
- under ADA/ADAAA, 117
- IEP development strategies influenced by, 116
- NJCLD guidelines, 116
- under RSA, 116
- unexpected underachievement as core aspect in, 130–131
- DSM-5 diagnostic criteria, 117–119
- for basic academic skills, 118
- for complex academic skills, 118
- IQ levels in, 118–119, 127
- under Education for All
- Handicapped Children Act, 116
- epidemiology, 119–122
- etiology, 119–122
- under Individuals with Disabilities Education Act, 116
- intervention/prevention strategies, 122–125, 129–130
- for adults, 130
- for MD, 129
- for RD, 122–124, 129
- LBW/preterm birth and, 7–10
- ADHD, 9
- diagnostic evaluations of, 14–15
- prevention strategies, 8–9
- special education services, 8
- MD, 120–121
- comorbidity with, 121
- developmental, 121
- genetic risk factors, 121
- intervention strategies, 129
- prevalence rates, 120–121
- pathophysiology, 119–122
- RD, 119–120
- brain development and, 120
- comorbidities with, 119–120
- intervention/prevention strategies, 122–124, 129
- meta-analysis of adults with, 123
- prevalence rates, 119
- risk factors for, 120
- testing for, limitations in, 125–130
- aptitude-achievement discrepancy model, 127
- discrepancy approaches, 129
- future strategies for, 130–133
- hybrid models, 128

## Index

- learning disabilities (LD). (cont.)  
 intra-individual differences model, 126–127  
 low achievement model, 126  
 regression to the mean model, 127–128  
 RTI model, 128
- learning skills. *See also* academic outcomes  
 with FASD, 85–86  
 non-verbal, 86  
 verbal, 85  
 with pediatric ischemic stroke, 253
- lesions  
 with MS, 229  
 with stroke, 254
- leukemias. *See specific leukemias*
- Lewy Body Disease (LBD), 268, 270, 271–273  
 behavioral features, 272  
 clinical features, 273  
 neuropsychological features, 272  
 specific assessment considerations, 279–280
- liquid tumors, 162
- low achievement model, 126
- low birth weight (LBW)  
 academic outcome issues with, 7–10  
 prevention strategies for, 8–9  
 special education services, 8  
 ASD and, social issues as result of, 9–10  
 classifications, 2  
 decline of, 2–3  
 defined, 2  
 developmental disorders  
 ADHD, 9  
 ASD and, 9–10  
 diagnosis of, 11  
 interventions for, 11–13  
 personality issues, 10–13  
 ELBW, 2  
 emotional issues and, 10  
 epidemiology, 2–16  
 intellectual disability and, 63  
 LBW, 2  
 learning disabilities and, 7–10  
 ADHD, 9  
 diagnostic evaluations of, 14–15  
 prevention strategies, 8–9  
 special education services, 8  
 mortality rates, 3  
 neurodevelopmental complications, 3, 4, 14–16  
 attention issues, 5–7  
 brain development, 4  
 cognitive ability, 5  
 CP, 3  
 diagnostic evaluations of, 14–15  
 EF deficits, 5–7
- IQ, 5  
 long-term, 4–16  
 PVL, 3  
 visuomotor skills, 7  
 pathophysiology, 2–16  
 personality issues, 10–13  
 corrected age evaluations, 10–11  
 prevalence rates for, 2  
 prevention strategies, 3  
 risk factors for, 2  
 WHO demographics for, 2
- LP birth. *See* late preterm birth
- MACFIMS. *See* Minimal Assessment of Cognitive Function in MS
- magnetic resonance imaging (MRI)  
 Flair, 247–248  
 fMRI  
 for ADHD, 96–97  
 for ASD diagnosis, 48
- Major and Mild Neurocognitive Disorders (NCDs), 268–269
- major depressive disorder (MDD), 95  
 males  
 ADHD in, 94  
 with FXS, 67
- math disorder (MD), 120–121  
 comorbidity with, 121  
 developmental, 121  
 genetic risk factors, 121  
 intervention strategies, 129  
 prevalence rates, 120–121
- MCA. *See* middle cerebral arteries
- MD. *See* math disorder
- MDD. *See* major depressive disorder
- medically refractory epilepsy, 192
- megencephaly, 48
- memory  
 with ASD, 50–51  
 recall ability, 51  
 epilepsy and, 193  
 neuropsychological assessment of, 200–201  
 with FASD, 85–86  
 non-verbal learning, 86  
 verbal learning, 85  
 with MS, 234  
 with pediatric cancer, 170, 171  
 with PHIV, 214  
 prospective, 27  
 retrospective, 27  
 with SBM, 27  
 intervention strategies for, 34–35  
 neuropsychological evaluations of, 32  
 with stroke, 257  
 pediatric ischemic stroke, 253  
 working, 27
- mental retardation, 61. *See also* intellectual disability
- metacognition, 26
- methylphenidate, 173
- middle cerebral arteries (MCA), 254
- mild TBI, 139, 140  
 assessment following, 147  
 clinical characteristics, 142  
 clinical implications, 153–154  
 intervention strategies, 150–151
- Minimal Assessment of Cognitive Function in MS (MACFIMS), 236
- mitoxantrone, 237–238
- MITP. *See* Mother-Infant Transaction Program
- moderately preterm (MP) birth, 2
- moderate-severe TBI, 142  
 AIM program, 152–153  
 assessment following, 147–148  
 clinical implications, 154  
 intervention strategies, 151–153  
 pharmacological interventions for, 153
- mood disorders, 45. *See also* anxiety disorder; depression  
 with HIV, 213  
 with MS, 235
- mortality rates  
 LBW/preterm birth, 3  
 SBM, 25
- mosaic trisomy, 64–65
- Mother-Infant Transaction Program (MITP), 12
- motor function  
 with ASD, 51  
 with DS, 65–66  
 with FASD, 86  
 with HIV, 213  
 with intellectual disability syndromes, 73  
 LBW/preterm birth and, 7  
 with pediatric cancer, 170  
 with pediatric ischemic stroke, 252–253  
 with SBM, 28  
 intervention strategies for, 35  
 neuropsychological evaluations of, 32
- MP birth. *See* moderately preterm birth
- MRI. *See* magnetic resonance imaging
- multiple sclerosis (MS)  
 clinical manifestations, 230–235  
 in children, 230  
 CIS, 233  
 clinical practice implications, 239  
 cognitive functioning, 234–235  
 in adults, 234  
 attention deficits, 234

- in children and adolescents, 234–235  
 EF, 235  
 language skills development, 234–235  
 memory deficits, 234  
 disease course, 233–234  
 epidemiology, 228–229  
 age of onset, 228  
 by gender, 228  
 by race, 228  
 etiology, 229  
 future research on, 239–240  
 interventions, 237–239  
 cognitive rehabilitation, 238–239  
 with corticosteroids, 237  
 pharmacological, 238  
 neuropsychological assessment, 235–236  
 BNBC, 236  
 BRB, 236  
 MACFIMS, 236  
 MS Society Neuropsychological Core Battery, 237  
 pathophysiology, 228–229  
 lesions, 229  
 pediatric, 229  
 prevention strategies, 229–230  
 psychosocial impact, 235  
 anxiety disorders, 235  
 depression, 235  
 fatigue, 235  
 mood disorders, 235
- natalizumab, 237  
 National Comprehensive Cancer Network (NCCN), 177  
 National Institute on Alcohol Abuse and Alcoholism (NIAAA), 79  
 National Joint Committee on Learning Disabilities (NJCLD), 116  
 Naturalistic, Developmental Behavioral Interventions (NBDI), 52  
 NCCN. *See* National Comprehensive Cancer Network  
 NCDs. *See* Major and Mild Neurocognitive Disorders  
 ND-PAE. *See* neurobehavioral disorder associated with prenatal alcohol exposure  
 neonates. *See* infants and children; low birth weight; preterm birth  
 neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE), 79–80  
 neuroimaging. *See also* functional magnetic resonance imaging for dementia, 277  
 neuropsychological functioning,  
 learning skills, 253. *See also* perinatal stroke  
 new-onset epilepsy, 194  
 NIAAA. *See* National Institute on Alcohol Abuse and Alcoholism  
 NJCLD. *See* National Joint Committee on Learning Disabilities  
 non-verbal learning, with FASD, 86  
 nutrition. *See* diet and nutrition
- obstructive sleep apnea (OSA), 249  
 oppositional defiant disorder (ODD), 9, 95  
 OSA. *See* obstructive sleep apnea
- PAE. *See* prenatal alcohol exposure  
 partial fetal alcohol syndrome (pFAS), 79  
 PBRT. *See* photon beam radiation therapy  
 PCA. *See* posterior cerebral arteries  
 pediatric cancer. *See also specific cancers*  
 assessment strategies, 173  
 Cogstate program, 178–179  
 behavioral functioning, 171–172  
 clinical manifestations, 166–167  
 clinical practice implications, 168  
 emotional functioning, 171–172  
 longitudinal outcomes, 171–172  
 interventions for, 173–175  
 cognitive, 174  
 educational, 174  
 future research on, 178, 179  
 online, 174–175  
 pharmacological, 173  
 socioemotional, 175  
 long-term effects into adulthood, 163  
 neuropsychological resources, 176  
 neuroanatomical correlates, 166–167  
 neuropsychological functioning with, 170–171  
 academic outcomes, 171  
 attention deficits, 170  
 EF, 170  
 genetic moderators of, 172  
 intellectual functioning, 170  
 memory functions, 170, 171  
 speed and motor functions, 170  
 pharmacological preventions, 169–170  
 psychosocial functioning, 171–172  
 longitudinal outcomes, 171–172  
 treatment strategies  
 chemoprotectants, 169  
 CRT, use limitations of, 169  
 hyperfractionation, 169  
 PBRT, 169  
 pediatric HIV (PHIV), 213–216  
 academic outcomes, 214–215  
 acquisition pre-birth, 211–212  
 adaptive functioning, 215  
 behavioral and emotional functioning, 215  
 cognitive functioning, 213–215  
 evidence-based guidelines, 221–223  
 language acquisition skills, 214–215  
 memory deficits, 214  
 pediatric ischemic stroke, 244  
 ADHD and, 253  
 aphasia, 256  
 clinical practices, 257, 260–261  
 hemispatial neglect, 256  
 heterogeneous population for, 255–256  
 intervention strategies, 258–260  
 rt-PA therapy, 258  
 neuropsychological functioning, 250–258  
 attention deficits, 253  
 cognitive functions, 257–258  
 EF, 253  
 intellectual ability, 250–252  
 language skills development, 252  
 learning skills, 253  
 memory deficits, 253  
 motor function, 252–253  
 post-stroke, 262–263  
 visual-spatial ability, 252–253  
 prevention strategies, 248–248, 258–260  
 risk factors, 246–247  
 social emotional functioning, 253–258  
 pediatric MS, 229  
 pediatric TBI. *See also* mild TBI; moderate-severe TBI  
 adult outcomes from, 145–146  
 behavioral and emotional outcomes, 144–145  
 clinical implications, 153–154  
 psychosocial outcomes, 145  
 return-to-school guidelines with, 150–151  
 perinatal stroke, 244  
 ADHD and, 253  
 assessment for, 256  
 MCA and, 254  
 neuropsychological functioning, 250–258  
 attention deficits, 253  
 EF, 253  
 intellectual ability, 250–252  
 language skills development, 252  
 learning skills, 253  
 memory deficits, 253



## Index

- perinatal stroke (cont.)  
 motor function, 252–253  
 visual-spatial ability, 252–253  
 risk factors, 246–247  
 periventricular leukomalacia (PVL), 3  
 personality deficits, LBW/preterm  
 birth and, 10–13  
 corrected age evaluations, 10–11  
 pFAS. *See* partial fetal alcohol  
 syndrome  
 phenobarbital, 168–169  
 phenylketonuria (PKU), 64  
 PHIV. *See* pediatric HIV  
 photon beam radiation therapy  
 (PBRT), 169  
 Pivotal Response Therapy (PRT), 52  
 PKU. *See* phenylketonuria  
 PNES. *See* psychogenic non-epileptic  
 seizures  
 posttraumatic amnesia (PTA), 139,  
 142–143, 147  
 posttraumatic epilepsy (PTE), 187–188  
 posttraumatic stress disorder (PTSD),  
 144–145  
 prenatal alcohol exposure (PAE), 79,  
 81  
 ADHD and, 86–87  
 ND-PAE, 79–80  
 preterm birth  
 academic outcome issues with, 7–10  
 prevention strategies for, 8–9  
 special education services, 8  
 ASD and, social issues as result of,  
 9–10  
 classifications, 2  
 decline of, 2–3  
 defined, 2  
 developmental disorders  
 ADHD, 9  
 ASD and, 9–10  
 diagnosis of, 11  
 interventions for, 11–13  
 personality issues, 10–13  
 emotional issues and, 10  
 EP, 2  
 epidemiology, 2–16  
 fertility treatments and, 2  
 intellectual disability and, 63  
 IUGR and, 2  
 learning disabilities and, 7–10  
 ADHD, 9  
 diagnostic evaluations of, 14–15  
 prevention strategies, 8–9  
 special education services, 8  
 LP, 2  
 medical complications, 3, 4  
 mortality rates, 3  
 MP, 2  
 neurodevelopmental complications,  
 3, 4, 14–16  
 attention issues, 5–7  
 brain development, 4  
 cognitive ability, 5  
 CP, 3  
 diagnostic evaluations of, 14–15  
 EF deficits, 5–7  
 IQ, 5  
 long-term, 4–16  
 PVL, 3  
 visuomotor skills, 7  
 pathophysiology, 2–16  
 personality issues, 10–13  
 corrected age evaluations, 10–11  
 prevalence rates for, 2  
 prevention strategies, 3  
 risk factors for, 2  
 SGA birth and, 2  
 VP, 2  
 WHO demographics for, 2  
 prospective memory, 27  
 PRT. *See* Pivotal Response Therapy  
 psychogenic non-epileptic seizures  
 (PNES), 197–199  
 PTA. *See* posttraumatic amnesia  
 PTE. *See* posttraumatic epilepsy  
 PTSD. *See* posttraumatic stress  
 disorder  
 PVL. *See* periventricular leukomalacia  
 race. *See also* African Americans; Asian  
 populations; Hispanic  
 populations  
 ADHD and, 94  
 birth defects and, 24  
 DS and, 65  
 MS and, 228  
 radiation therapy, 165  
 CRT, 163–164  
 for pediatric cancer, use  
 limitations in, 169  
 PBRT, 169  
 RBANS. *See* Repeatable Battery for the  
 Assessment of  
 Neuropsychological Status  
 reading disorder (RD), 119–120  
 brain development and, 120  
 comorbidities with, 119–120  
 intervention/prevention strategies,  
 122–124, 129  
 meta-analysis of adults with,  
 123  
 prevalence rates, 119  
 risk factors for, 120  
 recall ability, 51  
 recombinant tissue plasminogen  
 activator (rt-PA) therapy,  
 258  
 regression to the mean model, 127–128  
 Rehabilitation Services Administration  
 (RSA), 116  
 Repeatable Battery for the Assessment  
 of Neuropsychological Status  
 (RBANS), 278  
 response to intervention (RTI) model,  
 128  
 retrospective memory, 27  
 return-to-school guidelines, after TBI,  
 150–151  
 rituximab, 237  
 RSA. *See* Rehabilitation Services  
 Administration  
 RTI model. *See* response to  
 intervention model  
 rt-PA therapy. *See* recombinant tissue  
 plasminogen activator therapy  
 SBM. *See* spina bifida  
 myelomeningocele  
 SDB. *See* sleep disordered breathing  
 seizures, epileptic, 186  
 PNES, 197–199  
 SES. *See* socioeconomic status  
 severe TBI. *See* moderate-severe TBI  
 SGA birth. *See* small for gestational age  
 birth  
 sleep disordered breathing (SDB), 249  
 small for gestational age (SGA) birth  
 classifications, 2  
 preterm birth and, 2  
 social functioning  
 with ASD, 9–10, 47  
 with SBM, 29  
 intervention strategies for, 35–36  
 neuropsychological evaluations  
 of, 33  
 socioeconomic status (SES)  
 cancer treatment and, 169  
 SBM and, 29–30  
 solid tumors, 162  
 special education services, 8  
 IEP and, 33–34  
 spina bifida myelomeningocele (SBM)  
 during adolescence, 30  
 clinical manifestation, 25–31  
 academic outcomes, 28  
 ADHD, 26  
 attentional deficits, 25–26  
 EF deficits, 26–27  
 family functioning issues, 29–30  
 functional adaptation issues, 30  
 language deficits, 27  
 memory dysfunction, 27  
 metacognition deficits, 26  
 motor function deficits, 28  
 psychological dysfunction, 28–29  
 social functioning deficits, 29  
 visual-spatial abilities, 27–28  
 clinical treatment practices, 36–39  
 for academic outcome success, 37  
 anticipatory guidance, 37

- for developmental issues, 37  
 for EF, 37  
 through interprofessional team  
   partnering, with families, 36–37  
 through medical care, 37  
 for psychological functioning,  
   37–38  
 transition to adult care, 38  
 defined, 24  
 epidemiology of, 24–25  
 ETV/CPC and, 38–39  
 features, 24  
 HRQOL with, 29  
 intervention strategies, 33–37  
   for academic outcome success, 35  
   for attention deficits, 33–34  
   for EF, 34  
   for family functioning, 35–36  
   for functional adaptation, 36  
   for language skills development,  
     34  
   for memory deficits, 34–35  
   for motor functioning issues, 35  
   for psychological functioning,  
     35–36  
   for social functioning, 35–36  
   for visual-spatial difficulties, 35  
   vocational training, 37  
 mortality rates with, 25  
 neuropsychological evaluations  
   with, 30–33  
   for academic outcomes, 32–33  
   for attention deficits, 31  
   brain development, 31  
   for EF, 31  
   for family functioning, 33  
   for functional adaptation, 33  
   for language skills, 31–32  
   for memory, 32  
   for motor functioning, 32  
   for psychological functioning, 33  
   for social functioning, 33  
   for visual-spatial abilities, 32  
 pathophysiology, 24–25  
   Chiari-II malformation in, 25  
   hydrocephalus in, 25  
   non-genetic factors, 25  
 prevalence rates, by race, 24  
 prevention strategies, 25  
 tectal beaking and, 26  
 stroke. *See also* pediatric ischemic  
   stroke  
   cerebral atrophy, 254  
   clinical practices, 260–261  
   CSVD, 247, 248, 254  
   definitions, 244, 245  
   depression and, 262  
   diet and, 249  
   Flair MRI, 247–248  
   hemorrhagic, 244  
   AVM and, 247  
   risk factors, 247  
   incidence rates, 244  
   intervention strategies, 258–260  
   rt-PA therapy, 258  
   ischemic, 188  
   CSVT, 244  
   MCA and, 254  
   neuropsychological functioning,  
     250–258  
   cognitive functions, 257–258,  
     263–263  
   EF, 257–257  
   lesion location and, 254  
   memory deficits, 257  
   post-stroke, 262–263  
   OSA and, 249  
   prevention strategies, 248–250,  
     258–260  
   cholesterol level management, 249  
   diabetes management, 249  
   through lifestyle modification,  
     249–250  
   through medical management,  
     249  
   risk factors, 244, 259–259  
   atrial fibrillation, 249  
   SBD and, 249  
   types, 245  
   VCI and, 263–263  
 Sunitinib, 173–174  
 tamoxifen, 167–168  
 TBI. *See* traumatic brain injury  
 tectal beaking, 26  
 teriflunomide, 237  
 Theory of Visual Attention (TVA), 31  
 top-down attentional abilities, 26  
 topiramate, 168–169  
 training. *See* behavioral parent  
   training; facilitative  
   intervention training;  
   vocational training  
 translocation trisomy, 64–65  
 traumatic brain injury (TBI)  
   behavioral and emotional outcomes  
     with, 144–145  
     in adolescents, 145  
     in children, 144–145  
   blast injuries and, 140–141  
   clinical manifestations of, 141–142  
   cognitive characteristics, 141  
   magnitude of impairment,  
     141–142  
   mild TBI, 142  
   moderate-severe TBI, 142  
   neuroanatomical correlates, 141  
   neurobehavioral characteristics,  
     141  
   over time, 143  
   cognitive outcomes with, 141,  
     142–144  
   DAI, 140  
   definitions, 139  
     severity in, 139  
   dementia risks, 146–147  
     CTE, 146–147  
   diffuse, 140  
   epidemiology, 139  
   epilepsy after, 187–188  
   focal, 140  
   functional outcomes, 145  
   future research on, 154–155  
   intellectual disability from,  
     63, 64  
   intervention strategies, 149–154  
     for mild TBI, 150–151  
     moderate-severe TBI, 151–153  
     return-to-school guidelines, for  
       children, 150–151  
   mild, 139, 140  
     assessment following, 147  
     clinical characteristics, 142  
     clinical implications, 153–154  
     intervention strategies,  
       150–151  
   moderate-severe, 142  
     AIM program, 152–153  
     assessment following, 147–148  
     clinical implications, 154  
     intervention strategies, 151–153  
     pharmacological interventions  
       for, 153  
   pathophysiology, 140–141  
   pediatric. *See also* mild TBI;  
     moderate-severe TBI  
     adult outcomes from, 145–146  
     behavioral and emotional  
       outcomes, 144–145  
     clinical implications, 153–154  
     psychosocial outcomes, 145  
     return-to-school guidelines with,  
       150–151  
     prevention strategies, 148–149  
     psychosocial outcomes, 145  
       for children, 145  
       for families, 145  
     PTA and, 139, 142–143, 147  
     PTSD and, 144–145  
     treatment strategies, 149–150  
   trisomy 21, 64–65  
   TVA. *See* Theory of Visual Attention  
 UNAIDS. *See* Joint United Nations  
   Programme on HIV/AIDS  
 unexpected underachievement,  
   learning disabilities and,  
   130–131  
 universal prevention programs  
   (UPPSs), 81

**Index**

- vagal nerve stimulator (VNS), 202  
 vascular cognitive impairment (VCI), 263–263  
 verbal learning, with FASD, 85  
 very low birth weight (VLBW), 2  
 very preterm (VP) birth, 2  
 visual-spatial abilities  
   with FASD, 85  
   LBW/preterm birth and, 7  
   with pediatric ischemic stroke, 252–253  
   with SBM, 27–28  
     intervention strategies for, 35  
     neuropsychological evaluations of, 32  
 VLBW. *See* very low birth weight  
 VNS. *See* vagal nerve stimulator
- vocational training, as SBM  
   intervention strategy, 37  
 VP birth. *See* very preterm birth
- Wechsler Intelligence Scale for Children (WISC-V), 31  
 Wechsler Preschool and Primary Scale of Intelligence, Revised (WPPSI-R), 12  
 white matter development, with megencephaly, 48  
 WHO. *See* World Health Organization  
 Williams syndrome (WS), 67–68  
   comorbidities, 67  
   epidemiology, 67  
   etiology, 67  
   life expectancy, 68  
   neurobehavioral profile, 68  
   neurological basis, 68  
   phenotype, 67  
   prevalence, 67  
 WISC-V. *See* Wechsler Intelligence Scale for Children  
 women. *See also* low birth weight; preterm birth; small for gestational age birth  
   ADHD and, 94  
   FXS and, 67  
   MS and, 228  
 Woodcock-Johnson IV Tests of Achievement, 32  
 working memory, 27  
 World Health Organization (WHO), 2  
 WPPSI-R. *See* Wechsler Preschool and Primary Scale of Intelligence, Revised  
 WS. *See* Williams syndrome